Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CXCL10 elevation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

PD-L1 elevation + CXCL10 elevation + TNFA elevation (1)

CXCL10 elevation (0)

PD-L1 elevation + CXCL10 elevation + TNFA elevation (1)

CXCL10 elevation (0)

›

CXCL10 elevation	Uveal Melanoma	CXCL10 elevation	Uveal Melanoma	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3
CXCL10 elevation	Cutaneous Melanoma	CXCL10 elevation	Cutaneous Melanoma	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3
CXCL10 elevation	Endometrial Cancer	CXCL10 elevation	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3
CXCL10 elevation	Renal Cell Carcinoma	CXCL10 elevation	Renal Cell Carcinoma	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
CXCL10 elevation	Renal Cell Carcinoma	CXCL10 elevation	Renal Cell Carcinoma	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3
CXCL10 elevation	Renal Cell Carcinoma	CXCL10 elevation	Renal Cell Carcinoma	sunitinib + pazopanib Resistant: C3 – Early Trials sunitinib + pazopanib Resistant : C3	sunitinib + pazopanib Resistant: C3 – Early Trials sunitinib + pazopanib Resistant : C3
CXCL10 elevation	Acute Myelogenous Leukemia	CXCL10 elevation	Acute Myelogenous Leukemia	venetoclax Resistant: D – Preclinical venetoclax Resistant : D	venetoclax Resistant: D – Preclinical venetoclax Resistant : D